Mechanism of Action of Asciminib
Introduction Asciminib is an oral targeted anticancer drug marketed under the brand name Scemblix. Pharmacologically, asciminib is an ABL/BCR-ABL1 tyrosine kinase inhibitor used in Philadelphia chromosome-positive chronic myeloid leukemia, commonly abbreviated as Ph+ CML. Chronic myeloid leukemia is driven by the Philadelphia chromosome, which forms due to a translocation between chromosomes 9 and 22. This … Read more